Free Access
Med Sci (Paris)
Volume 21, Number 3, Mars 2005
Page(s) 253 - 260
Section M/S revues
Published online 15 March 2005
  1. Nilsen TW. The spliceosome : the most complex macromolecular machine in the cell ? BioEssays 2003; 25 : 1147–9. [Google Scholar]
  2. Caceres JF, Kornblihtt AR. Alternative splicing : multiple control mechanisms and involvement in human disease. Trends Genet 2002; 18 : 186–93. [Google Scholar]
  3. Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. Genes Dev 2003; 17 : 419–37. [Google Scholar]
  4. Nissim-Rafinia M, Kerem B. Splicing regulation as a potential genetic modifier. Trends Genet 2002; 18 : 123–7. [Google Scholar]
  5. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 2003; 72 : 291–336. [Google Scholar]
  6. Modrek B, Resch A, Grasso C, Lee C. Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res 2001; 29 : 2850–9. [Google Scholar]
  7. Hanke J, Brett D, Zastrow I, et al. Alternative splicing of human genes : more the rule than the exception ? Trends Genet 1999; 15 : 389–90. [Google Scholar]
  8. Modrek B, Lee C. A genomic view of alternative splicing. Nat Genet 2002; 30 : 13–9. [Google Scholar]
  9. Nagy E, Maquat LE. A rule for termination-codon position within intron-containing genes : when nonsense affects RNA abundance. Trends Biochem Sci 1998; 23 : 198–9. [Google Scholar]
  10. Proudfoot N. Connecting transcription to messenger RNA processing. Trends Biochem Sci 2000; 25 : 290–3. [Google Scholar]
  11. Logette E, Wotawa A, Solier S, et al. The human caspase-2 gene : alternative promoters, pre-mRNA splicing and AUG usage direct isoform-specific expression. Oncogene 2003; 22 : 935–46. [Google Scholar]
  12. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense : exonic mutations that affect splicing. Nat Rev Genet 2002; 3 : 285–98. [Google Scholar]
  13. Brinkman BM. Splice variants as cancer biomarkers Clin Biochem 2004; 37 : 584–94. [Google Scholar]
  14. Garcia-Blanco MA, Baraniak AP, Lasda EL. Alternative splicing in disease and therapy. Nat Biotechnol 2004; 22 : 535–46. [Google Scholar]
  15. Roberts GC, Smith CW. Alternative splicing : combinatorial output from the genome. Curr Opin Chem Biol 2002; 6 : 375–83. [Google Scholar]
  16. Yeakley JM, Fan JB, Doucet D, et al. Profiling alternative splicing on fiber-optic arrays. Nat Biotechnol 2002; 20 : 353–8. [Google Scholar]
  17. Zhu J, Shendure J, Mitra RD, Church GM. Single molecule profiling of alternative pre-mRNA splicing. Science 2003; 301 : 836–8. [Google Scholar]
  18. Jin P, Fu GK, Wilson AD, et al. PCR isolation and cloning of novel splice variant mRNAs from known drug target genes. Genomics 2004; 83 : 566–71. [Google Scholar]
  19. Lareau LF, Green RE, Bhatnagar RS, Brenner SE. The evolving roles of alternative splicing. Curr Opin Struct Biol 2004; 14 : 273–82. [Google Scholar]
  20. Stickeler E, Kittrell F, Medina D, Berget SM. Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene 1999; 18 : 3574–8. [Google Scholar]
  21. Yamaguchi F, Saya H, Bruner JM, Morrison RS. Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci USA 1994; 91 : 484–8. [Google Scholar]
  22. Sneath RJ, Mangham DC. The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 1998; 51 : 191–200. [Google Scholar]
  23. Thakur S, Zhang HB, Peng Y, et al. Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol Cell Biol 1997; 17 : 444–52. [Google Scholar]
  24. Nissim-Rafinia M, Kerem B. Splicing regulation as a potential genetic modifier. Trends Genet 2002; 18 : 123–7. [Google Scholar]
  25. Nissim-Rafinia M, Chiba-Falek O, Sharon G, et al. Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations. Hum Mol Genet 2000; 9 : 1771–8. [Google Scholar]
  26. Hofmann Y, Lorson CL, Stamm S, et al. Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc Natl Acad Sci USA 2000; 97 : 9618–23. [Google Scholar]
  27. Wu JY, Tang H, Havlioglu N. Alternative pre-mRNA splicing and regulation of programmed cell death. Prog Mol Subcell Biol 2003; 31 : 153–85. [Google Scholar]
  28. Pilch B, Allemand E, Facompre M, et al. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. Cancer Res 2001; 61 : 6876–84. [Google Scholar]
  29. Cartegni L, Krainer AR. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol 2003; 10 : 120–5. [Google Scholar]
  30. Chang JG, Hsieh-Li HM, Jong YJ, et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 2001; 98 : 9808–13. [Google Scholar]
  31. Andreassi C, Jarecki J, Zhou J, et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 2001; 10 : 2841–9. [Google Scholar]
  32. Wotawa A, Solier S, Logette E, et al. Differential influence of etoposide on two caspase-2 mRNA isoforms in leukemic cells. Cancer Lett 2002; 185 : 181–9. [Google Scholar]
  33. Solier S, Lansiaux A, Logette E, et al. Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Mol Cancer Res 2004; 2 : 53–61. [Google Scholar]
  34. Aubœuf D, Honig A, Berget SM, O’Malley BW. Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science 2002; 298 : 416–9. [Google Scholar]
  35. Lu QL, Mann CJ, Lou F, et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 2003; 9 : 1009–14. [Google Scholar]
  36. Goyenvalle A, Vulin A, Fougerousse F, et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 2004; 306 : 1746–9. [Google Scholar]
  37. Skordis LA, Dunckley MG, Yue B, et al. Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci USA 2003; 100 : 4114–9. [Google Scholar]
  38. Cartegni L, Krainer AR. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol 2003; 10 : 120–5. [Google Scholar]
  39. Villemaire J, Dion I, Elela SA, Chabot B. Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides. J Biol Chem 2003; 278 : 50031–9. [Google Scholar]
  40. Celotto AM, Graveley BR. Exon-specific RNAi : a tool for dissecting the functional relevance of alternative splicing. RNA 2002; 8 : 718–24. [Google Scholar]
  41. Chao H, Mansfield SG, Bartel RC, et al. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat Med 2003; 9 : 1015–9. [Google Scholar]
  42. Rogers CS, Vanoye CG, Sullenger BA, George AL Jr. Functional repair of a mutant chloride channel using a trans-splicing ribozyme. J Clin Invest 2002; 110 : 1783–9. [Google Scholar]
  43. Deidda G, Rossi N, Tocchini-Valentini GP. An archaeal endoribonuclease catalyzes cis- and trans- nonspliceosomal splicing in mouse cells. Nat Biotechnol 2003; 21 : 1499–504. [Google Scholar]
  44. Burge CB, Tuschl T, Sharp PA. Splicing of precursors to mRNAs by the spliceosomes. In : Gesteland RF, Cech TR, Atkins JF, eds. The RNA world II. Cold Spring Harbor-New York : Cold Spring Harbor Laboratory Press, 1999 : 525–60. [Google Scholar]
  45. Sanford JR, Bruzick JP. Developmental regulation of SR protein phosphorylation and activity. Genes Dev 1999; 13 : 1513–8. [Google Scholar]
  46. Mistelli T, Spector DL. The cellular organization of gene expression. Curr Opin Cell Biol 1998; 10 : 323–31. [Google Scholar]
  47. Murray MV. Role of phosphorylation in pre-mRNA splicing. Front Horm Res 1999; 25 : 83–100. [Google Scholar]
  48. Dreyfuss G, Matunis MJ, Piñol-Roma S, Burd CG. HnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem 1993; 63 : 289–321. [Google Scholar]
  49. Sazani P, Kole R. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest 2003; 112 : 481–6. [Google Scholar]
  50. Mann CJ, Honeyman K, Cheng AJ, et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 2001; 98 : 42–7. [Google Scholar]
  51. Mercatante DR, Mohler JL, Kole R. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J Biol Chem 2002; 277 : 49374–82. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.